|Bid||141.86 x 2900|
|Ask||142.00 x 1200|
|Day's range||140.23 - 156.32|
|52-week range||76.59 - 331.68|
|Beta (5Y monthly)||1.59|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||264.20|
Dr. Ben Weston, Milwaukee COVID-19 Emergency Operations Center Medical Director, talks about the process of approving the COVID-19 vaccine for children and the global fight against COVID-19.
Shares of Novavax (NASDAQ: NVAX) were jumping 6.1% higher as of 10:48 a.m. EDT on Wednesday after rising as much as 15.8% earlier in the morning. The nice gain came following the company's announcement that it has filed for authorization of its COVID-19 vaccine NVX-CoV2373 to the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). Novavax's U.K. submission is an important milestone for the company.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate. The company's application for Conditional Marketing Authorization (CMA) marks the first submission for authorization of a protein-based COVID-19 vaccine